OBJECTIVE: Ganglioside-induced differentiation associated-protein 1 (GDAP1) mutations are commonly associated with autosomal recessive Charcot-Marie-Tooth (ARCMT) neuropathy; however, in rare instances, they also lead to autosomal dominant Charcot-Marie-Tooth (ADCMT). We aimed to investigate the frequency of disease-causing heterozygous GDAP1 mutations in ADCMT and their associated phenotype. METHODS: We performed mutation analysis in a large cohort of ADCMT patients by means of bidirectional sequencing of coding regions and exon-intron boundaries of GDAP1. Intragenic GDAP1 deletions were excluded using an allele quantification assay. We confirmed the pathogenic character of one sequence variant by in vitro experiments assaying mitochondrial morphology and function. RESULTS: In 8 Charcot-Marie-Tooth disease (CMT) families we identified 4 pathogenic heterozygous GDAP1 mutations, 3 of which are novel. Three of the mutations displayed reduced disease penetrance. Disease onset in the affected individuals was variable, ranging from early childhood to adulthood. Disease progression was slow in most patients and overall severity milder than typically seen in autosomal recessive GDAP1 mutations. Electrophysiologic changes are heterogeneous but compatible with axonal neuropathy in the majority of patients. CONCLUSIONS: With this study, we broaden the phenotypic and genetic spectrum of autosomal dominant GDAP1-associated neuropathies. We show that patients with dominant GDAP1 mutations may display clear axonal CMT, but may also have only minimal clinical and electrophysiologic abnormalities. We demonstrate that cell-based functional assays can be reliably used to test the pathogenicity of unknown variants. We discuss the implications of phenotypic variability and the reduced penetrance of autosomal dominant GDAP1 mutations for CMT diagnostic testing and counseling.
OBJECTIVE: Ganglioside-induced differentiation associated-protein 1 (GDAP1) mutations are commonly associated with autosomal recessive Charcot-Marie-Tooth (ARCMT) neuropathy; however, in rare instances, they also lead to autosomal dominant Charcot-Marie-Tooth (ADCMT). We aimed to investigate the frequency of disease-causing heterozygous GDAP1 mutations in ADCMT and their associated phenotype. METHODS: We performed mutation analysis in a large cohort of ADCMT patients by means of bidirectional sequencing of coding regions and exon-intron boundaries of GDAP1. Intragenic GDAP1 deletions were excluded using an allele quantification assay. We confirmed the pathogenic character of one sequence variant by in vitro experiments assaying mitochondrial morphology and function. RESULTS: In 8 Charcot-Marie-Tooth disease (CMT) families we identified 4 pathogenic heterozygous GDAP1 mutations, 3 of which are novel. Three of the mutations displayed reduced disease penetrance. Disease onset in the affected individuals was variable, ranging from early childhood to adulthood. Disease progression was slow in most patients and overall severity milder than typically seen in autosomal recessive GDAP1 mutations. Electrophysiologic changes are heterogeneous but compatible with axonal neuropathy in the majority of patients. CONCLUSIONS: With this study, we broaden the phenotypic and genetic spectrum of autosomal dominant GDAP1-associated neuropathies. We show that patients with dominant GDAP1 mutations may display clear axonal CMT, but may also have only minimal clinical and electrophysiologic abnormalities. We demonstrate that cell-based functional assays can be reliably used to test the pathogenicity of unknown variants. We discuss the implications of phenotypic variability and the reduced penetrance of autosomal dominant GDAP1 mutations for CMT diagnostic testing and counseling.
Authors: Imke Puls; Catherine Jonnakuty; Bernadette H LaMonte; Erika L F Holzbaur; Mariko Tokito; Eric Mann; Mary Kay Floeter; Kimberly Bidus; Dennis Drayna; Shin J Oh; Robert H Brown; Christy L Ludlow; Kenneth H Fischbeck Journal: Nat Genet Date: 2003-03-10 Impact factor: 38.330
Authors: O Dubourg; H Azzedine; C Verny; G Durosier; N Birouk; R Gouider; M Salih; A Bouhouche; A Thiam; D Grid; M Mayer; M Ruberg; M Tazir; A Brice; E LeGuern Journal: Neuromolecular Med Date: 2006 Impact factor: 3.843
Authors: P De Jonghe; I Mersivanova; E Nelis; J Del Favero; J J Martin; C Van Broeckhoven; O Evgrafov; V Timmerman Journal: Ann Neurol Date: 2001-02 Impact factor: 10.422
Authors: Magdalena Zimoń; Jonathan Baets; Michaela Auer-Grumbach; José Berciano; Antonio Garcia; Eduardo Lopez-Laso; Luciano Merlini; David Hilton-Jones; Meriel McEntagart; Andrew H Crosby; Nina Barisic; Eugen Boltshauser; Christopher E Shaw; Guida Landouré; Christy L Ludlow; Rachelle Gaudet; Henry Houlden; Mary M Reilly; Kenneth H Fischbeck; Charlotte J Sumner; Vincent Timmerman; Albena Jordanova; Peter De Jonghe Journal: Brain Date: 2010-05-11 Impact factor: 13.501
Authors: Nadia Ammar; Eva Nelis; Luciano Merlini; Nina Barisić; Rim Amouri; Chantal Ceuterick; Jean Jacques Martin; Vincent Timmerman; Fayçal Hentati; Peter De Jonghe Journal: Neuromuscul Disord Date: 2003-11 Impact factor: 4.296
Authors: Rafael Sivera; Teresa Sevilla; Juan Jesús Vílchez; Dolores Martínez-Rubio; María José Chumillas; Juan Francisco Vázquez; Nuria Muelas; Luis Bataller; José María Millán; Fancesc Palau; Carmen Espinós Journal: Neurology Date: 2013-09-27 Impact factor: 9.910
Authors: Jonathan D J Labonne; Kang-Han Lee; Shigeki Iwase; Il-Keun Kong; Michael P Diamond; Lawrence C Layman; Cheol-Hee Kim; Hyung-Goo Kim Journal: Hum Genet Date: 2016-04-22 Impact factor: 4.132
Authors: José Berciano; Antonio García; Elena Gallardo; Kristien Peeters; Ana L Pelayo-Negro; Silvia Álvarez-Paradelo; José Gazulla; Miriam Martínez-Tames; Jon Infante; Albena Jordanova Journal: J Neurol Date: 2017-03-31 Impact factor: 4.849
Authors: Mari Auranen; Emil Ylikallio; Jussi Toppila; Mirja Somer; Sari Kiuru-Enari; Henna Tyynismaa Journal: Neurogenetics Date: 2013-03-03 Impact factor: 2.660